XML 49 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue and Accounts Receivable Credit Concentration (Tables)
12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Summary of Revenue

Revenues consisted of the following (in thousands):

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

Diagnostic tests

 

$

34,538

 

 

$

48,937

 

Services

 

 

3,674

 

 

 

5,569

 

Total revenue

 

$

38,212

 

 

$

54,506

 

Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

The State of Colorado

 

 

10

%

 

 

 

The Big Ten Conference

 

 

 

 

 

40

%

In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 37% and 18% of the Company’s total revenue for the years ended December 31, 2022 and 2021, respectively. The Company is subject to credit risk from its accounts receivable related to services provided to its customers.

 

 

As of December 31,

 

 

 

2022

 

 

2021

 

Medicare

 

 

23

%

 

 

30

%

Astrazeneca UK

 

 

18

%

 

 

 

Janssen Research and Development, LLC

 

 

 

 

 

14

%

LabCorp DD (formerly Covance)

 

 

 

 

 

11

%